- Home
- MAIN vs AXSM Comparison
MAIN vs AXSM Comparison
Compare MAIN & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MAIN | AXSM |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MAIN | AXSM |
|---|---|---|
| Price | $61.84 | $148.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | $61.57 | ★ $176.00 |
| AVG Volume (30 Days) | 455.4K | ★ 519.5K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 6.87% | N/A |
| EPS Growth | ★ 9.38 | N/A |
| EPS | ★ 6.03 | N/A |
| Revenue | ★ $561,290,000.00 | $561,263,000.00 |
| Revenue This Year | $5.53 | $66.20 |
| Revenue Next Year | $2.24 | $57.56 |
| P/E Ratio | $10.29 | ★ N/A |
| Revenue Growth | 5.92 | ★ 65.83 |
| 52 Week Low | $47.00 | $75.56 |
| 52 Week High | $67.77 | $152.94 |
Technical Indicators
Market Signals| Indicator | MAIN | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 67.04 | 56.94 |
| Support Level | $57.57 | $144.00 |
| Resistance Level | $63.21 | $150.00 |
| Average True Range (ATR) | 1.02 | 4.15 |
| MACD | 0.57 | -0.73 |
| Stochastic Oscillator | 85.93 | 57.42 |
Price Performance
Historical ComparisonAbout MAIN Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancing, and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants, and other securities of the lower middle market and middle market companies based in the United States. Business functioned through the U.S. region and it derives the majority of its income from the source of fees, commission, and interest.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.